Category: Partners

Highlights:

• Portal construction commenced with initial blast completed

• Underground operations expected to contribute to production in June and ramp up during Q3 2025

• Open pit exploration drill campaign commenced

TORONTO, ONTARIO / ACCESS Newswire / June 12, 2025 / Cerrado Gold Inc. [TSX.V:CERT][OTCQX:CRDOF][FRA:BAI0] (“Cerrado” or the “Company“) is pleased to provide an update on the development of the Company’s inaugural underground operation commencing underneath the high-grade Paloma pit at its Minera Don Nicolas Mine in Argentina (“MDN”).

Earlier this week, the Company completed the initial blast to begin construction of the underground portal and progress the development of the underground mine over the coming months. The initial decline will be driven through the ore body and will provide nominal feed to the carbon in leach (“CIL”) plant. Production from the underground is expected to ramp-up to reach steady state production by October this year.

Additionally, the Company has now mobilized the initial drill rig to commence the previously announced 20,000 metre exploration drill program at MDN. The primary focus will be near surface, high-grade deposits that can provide feed to the CIL plant as well as expanding potential resources in and around the Las Calandrias heap leach project to add both high grade and heap leachable material. Underground drilling at Paloma will commence once the underground exploration platforms have been established.

Mark Brennan, Executive Chairman, commented: “The start of the underground operation is a key milestone for Cerrado’s Argentinian operations; we now have the ability to produce from open pit, heap leach and underground operations. Not only will the underground operations contribute to production immediately, but it will also provide a platform for underground exploration, which remains completely open and largely unexplored at MDN.”

Review of Technical Information

The scientific and technical information in this press release has been reviewed and approved by Andrew Croal, P.Eng., Chief Technical Officer for Cerrado Gold, who is a Qualified Person as defined in National Instrument 43-101.

About Cerrado

Cerrado Gold is a Toronto-based gold production, development, and exploration company. The Company is the 100% owner of the producing Minera Don Nicolás and Las Calandrias mine in Santa Cruz province, Argentina. In Portugal, the Company holds an 80% interest in the highly prospective Lagoa Salgada VMS project through its position in Redcorp – Empreendimentos Mineiros, Lda. In Canada, Cerrado Gold is developing its 100% owned Mont Sorcier Iron project located outside of Chibougamou, Quebec.

In Argentina, Cerrado is maximizing asset value at its Minera Don Nicolas (“MDN”) operation through continued operational optimization and is growing production through its operations at the Las Calandrias heap leach project. An extensive campaign of exploration is ongoing to further unlock potential resources in our highly prospective land package in the heart of the Deseado Masiff.

In Portugal, Cerrado is focused on the development and exploration of the highly prospective Lagoa Salgada VMS project located on the prolific Iberian Pyrite Belt in Portugal. The Lagoa Salgada project is a high-grade polymetallic project, demonstrating a typical mineralization endowment of zinc, copper, lead, tin, silver, and gold. Extensive exploration upside potential lies both near deposit and at prospective step-out targets across the large 7,209-hectare property concession. Located just 80km from Lisbon and surrounded by exceptional infrastructure, Lagoa Salgada offers a low-cost entry to a significant development and exploration opportunity, already showing its mineable scale and cashflow generation potential.

In Canada, Cerrado holds a 100% interest in the Mont Sorcier high purity high grade DRI Iron Ore project, which has the potential to produce a premium iron ore concentrate over a long mine life at low operating costs and low capital intensity. Furthermore, its high grade and high purity product facilitates the migration of steel producers from blast furnaces to electric arc furnaces, contributing to the decarbonization of the industry and the achievement of sustainable development goals.

For more information about Cerrado please visit our website at: www.cerradogold.com.

Mark Brennan
CEO and Chairman

Mike McAllister
Vice President, Investor Relations
Tel: +1-647-805-5662
mmcallister@cerradogold.com

Disclaimer

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This press release contains statements that constitute “forward-looking information” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

Forward-looking statements contained in this press release include, without limitation, statements regarding the business and operations of Cerrado, the Company’s 2025 guidance including expected gold production, future growth, the goals of our planned underground exploration program, the expected timing of the strengthening of the 2025 production, the primary sources of the 2025 production, expectations regarding production at the underground operation. Forward-looking statements and forward-looking information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information.

In making the forward-looking statements contained in this press release, Cerrado has made certain assumptions. Although Cerrado believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurance that the expectations of any forward-looking statements will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Except as required by law, Cerrado disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

SOURCE: Cerrado Gold Inc.

View the original press release on ACCESS Newswire

NORTH BILLERICA, MA / ACCESS Newswire / June 11, 2025 / Tecogen Inc. (NYSE American:TGEN) a leading manufacturer of clean energy products, today announced that Abinand Rangesh, Chief Executive Officer, will participate in the 15^th Annual Roth Conference hosted in London, England on June 24^th to 26^th, 2025. Management will be available for one-on-one meetings during the conference.

Attending investors interested in meeting Dr. Rangesh should contact their Roth representative or email investorrelations@tecogen.com.

About Tecogen

Tecogen designs, manufactures, sells, installs, and maintains high efficiency, ultra-clean, cogeneration products including engine-driven combined heat and power, air conditioning systems, and high-efficiency water heaters for residential, commercial, recreational and industrial use. The company provides cost effective, environmentally friendly and reliable products for energy production that nearly eliminate criteria pollutants and significantly reduce a customer’s carbon footprint. In business for over 35 years, Tecogen has shipped more than 3,200 units, supported by an established network of engineering, sales, and service personnel in key markets in North America. For more information, please visit www.tecogen.com or contact us for a free Site Assessment.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and other federal securities laws that involve a number of risks and uncertainties. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “project,” “target,” “potential,” “will,” “should,” “seek,” “could,” “likely,” “may,” “pro forma,” “anticipate,” “continue,” or other variations thereof (including their use in the negative), or by discussions of strategies, plans or intentions. All statements, other than statements of historical fact included in this press release regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management are forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update or revise any forward-looking statements.

In addition to those factors described in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and in our Form 8-K, under “Risk Factors,” among the factors that could cause actual results to differ materially from past and projected future results are the following: fluctuations in demand for our products and services, competing technological developments, issues relating to research and development, the availability of incentives, rebates, and tax benefits relating to our products and services, changes in the regulatory environment relating to our products and services, integration of acquired business operations, and the ability to obtain financing on favorable terms to fund existing operations and anticipated growth.

Tecogen Media & Investor Relations Contact Information:

Abinand Rangesh, CEO
P: 781-466-6487
E: Abinand.Rangesh@tecogen.com

SOURCE: Tecogen, Inc.

View the original press release on ACCESS Newswire

Drive to Thrive

NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Skip Barber Racing School, North America’s premier racing instruction program, and Griiip, a global motorsport data technology innovator, today announced a multi-year strategic partnership to bring cutting-edge data analytics, live insights, and digital coaching tools to the world of driver development, both on and off the track.

Through the integration of Griiip’s proprietary GriiipPerformance and GriiipLive platforms, the collaboration introduces an immersive, fully connected training and fan engagement ecosystem across Skip Barber’s racing and sim racing programs.

“This collaboration with Griiip marks an exciting evolution for all our programs,” said Michael Berg, CFO, Skip Barber Racing School. “The ability to offer every student and instructor a seamless, data-rich experience will elevate our training, create more value for our customers, and allow us to stay connected with students between track days.”

Key Features & Benefits:

• Connected Racing Fleet: Beginning with formula cars, IturanMOB hardware will stream real-time telemetry and video to the Griiip Cloud for instant analysis and feedback.

• AI-Powered Coaching: Actionable insights, personalized guidance, and seamless data-video integration for drivers and instructors.

• Centralized Digital Profiles: All session data, video, and analytics in one place, across track and sim.

• Performance Benchmarking: Tools to track progress, identify growth areas, and compare against peers.

• Fan Tools: Second-Screen Engagement (GriiipLive) enables fans to follow races with enriched live data and insights.

Griiip CEO Tamir Plachinsky added, “We’re proud to partner with a brand as iconic as Skip Barber. Together, we’re setting a new standard for motorsport education: smarter, more connected, and more accessible for both drivers and fans.”

Implementation has already begun with GriiipLive deployed in the Skip Barber Formula Race Series and iRacing Sim Series, while GriiipPerformance is being integrated into Skip Barber’s Long Island simulator center for year-round training capabilities.

As motorsport embraces a data-driven future, Skip Barber and Griiip are leading the charge, empowering the next generation of drivers with professional-grade tools previously reserved for elite teams.

About Griiip

Griiip is redefining motorsport intelligence with advanced analytics and AI-powered tools. Its GriiipLive and GriiipPerformance platforms transform raw data into real-time insights and engaging experiences for drivers, teams, fans, and media, across both real-world and virtual racing.

About Skip Barber Racing School

Celebrating our 50th anniversary, Skip Barber Racing School is the most recognized name in driver training and racing instruction in North America. Thousands of professional and amateur drivers have launched their careers through its programs, spanning high-performance driving to professional racing series.

Media Contacts: Griiip Automotive Engineering Ltd media@griiip.com | +1 212 555 0145

Skip Barber Racing School press@skipbarber.com | +1 860 435 1300

SOURCE: New To The Street

View the original press release on ACCESS Newswire

Distinguished Diplomat Joins Former Labor Secretary Alex Acosta on Public Company Board

BOCA RATON, FL / ACCESS Newswire / June 11, 2025 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) today announced the appointment of Ambassador Paula J. Dobriansky to the Company’s Board of Directors, effective immediately. Dobriansky will serve as a member of the Audit Committee alongside former U.S. Secretary of Labor Alex Acosta, who was appointed to the Board upon the closing of the Company’s initial public offering in March of this year.

“We are delighted to officially welcome Secretary Acosta and announce the addition of Ambassador Dobriansky to our Board of Directors,” said Chris Ruddy, CEO of Newsmax. “Their exceptional backgrounds in public service, regulatory policy and international affairs will provide valuable perspectives as we continue to execute our growth strategy and deliver trusted news to the American people and countries around the world.”

Ambassador Dobriansky and Secretary Acosta join the five member Newsmax Board of Directors that includes its CEO, Chris Ruddy, Ambassador Nancy Brinker and Christopher Nixon Cox.

Ambassador Paula J. Dobriansky

Ambassador Paula J. Dobriansky, a foreign policy expert and diplomat specializing in national security affairs, is Vice Chair of the Atlantic Council’s Scowcroft Center for Strategy and Security and a Senior Fellow at Harvard University’s John F. Kennedy Belfer Center for Science and International Affairs. She brings over 30 years of government and international experience across senior levels of diplomacy, business and defense.

From 2010 to 2012, she was Senior Vice President and Global Head of Government and Regulatory Affairs at Thomson Reuters, responsible for designing and implementing a corporate approach for engagement in Washington and other key capitals around the globe. During this time, she was also appointed the Distinguished National Security Chair at the U.S. Naval Academy. 

Dobriansky served as Under Secretary of State for Global Affairs from 2001 to 2009. In February 2007, as the President’s Envoy to Northern Ireland, she received the Secretary of State’s highest honor, the Distinguished Service Medal, for her contribution to the historic devolution of power in Belfast.

During President Donald J. Trump’s Administration, Dobriansky served on the Defense Policy Board, the Secretary of State’s Foreign Affairs Policy Board and as Chair of the U.S. Export-Import Bank’s Council on China Competition.

Ambassador Dobriansky received a BSFS summa cum laude in international politics from Georgetown University School of Foreign Service, as well as an MA and PhD in Soviet political and military affairs from Harvard University. She is a member of the Council on Foreign Relations and the American Academy of Diplomacy, and she has received high-level international recognition from the governments of Poland, Ukraine, Hungary, Romania, Lithuania, the Czech Republic and Colombia and is the recipient of five honorary degrees.

Secretary R. Alex Acosta

Secretary Alex Acosta served as the 27^th United States Secretary of Labor. He is the son of Cuban refugees and a first-generation college graduate, earning his undergraduate and law degrees from Harvard University.

Mr. Acosta’s diverse experiences include serving as Chairman of U.S. Century Bank, as Dean of the FIU College of Law, as U.S. Attorney and Assistant Attorney General at the Department of Justice, as a Member of the National Labor Relations Board, as a Senior Fellow at the Ethics & Public Policy Center and as an analyst at Lehman Brothers. Following law school, Mr. Acosta worked as a law clerk for then U.S. Court of Appeals Judge Samuel A. Alito, and as an associate, primarily in labor law and in appeals, at Kirkland & Ellis.

Mr. Acosta has served in four presidentially appointed, Senate confirmed positions. In 2002, Mr. Acosta was confirmed as a Member of the National Labor Relations Board. In 2003, he was confirmed Assistant Attorney General for the Civil Rights Division of the U.S. Department of Justice. From 2005 to 2009, Mr. Acosta served as the U.S. Attorney for the Southern District of Florida.

From 2009 through 2016, Mr. Acosta served as the dean of the FIU College of Law, a majority-Hispanic law school. During his tenure, FIU Law flourished: FIU’s U.S. News & World Report’s ranking increased faster than any law school in the nation.

In December 2013, Mr. Acosta was named Chairman of U.S. Century Bank, (USCB). Mr. Acosta served as chairman through May 2017, successfully leading a recapitalization and management renewal that resulted in an exit from TARP, a return to profitability, an extraordinary improvement in asset quality and a lifting of the FDIC consent order.

In February 2017, President Donald Trump nominated Mr. Acosta to serve as Secretary of Labor. Secretary Acosta focused on addressing the nation’s skills gap, advocating for expansion of apprenticeship programs and for other skills acquisition programs that provide in-demand skills.

Mr. Acosta also served as Chairman of the Pension Benefit Guaranty Corporation and Board Member of the Overseas Private Investment Corporation. Secretary Acosta presently serves on the Newsmax Board of Directors and as Audit Committee Chair, and as a speaker and an advisor to private market ventures.

For more information on Newsmax’s Board of Directors, please visit Investor Relations | Newsmax, Inc.

Financial Guidance

Alongside today’s announcement, Newsmax is issuing full-year revenue guidance for FY 2025 ending December 31. The Company expects total revenue to be in the range of $180 million to $190 million.

This guidance reflects management’s current expectations and is subject to risks and uncertainties, as further described herein.

About Newsmax

Newsmax Media, Inc. operates Newsmax, the nation’s fourth highest-rated cable news network, according to Nielsen. Newsmax is carried on all major cable, satellite systems, and virtual pay TV operators. Newsmax reaches more than 40 million Americans regularly through Newsmax TV, the Newsmax+ App, its popular website Newsmax.com, and publications like Newsmax Magazine. Reuters Institute says Newsmax is one of the top 12 U.S. news brands and Forbes has called us “a news powerhouse.”

For more information, please visit Investor Relations | Newsmax, Inc.

Forward-Looking Statements

This communication contains forward-looking statements. From time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Forward-looking statements can be identified by those that are not historical in nature. The forward-looking statements discussed in this communication and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. Newsmax does not guarantee future results, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this communication to conform our prior statements to actual results or revised expectations, and we do not intend to do so. Factors that may cause actual results to differ materially from current expectations include various factors, including but not limited to the factors set forth in the sections entitled “Risk Factors” in Newsmax’s Annual Report on Form 10-K for the twelve months ended December 31, 2024, Newsmax’s Quarterly Report on Form 10-Q for the three months ended March 31, 2025, and other filings Newsmax makes with the Securities and Exchange Commission. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Undue reliance should not be placed on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein.

Investor Contacts

Newsmax Investor Relations
ir@newsmax.com

SOURCE: Newsmax Inc.

View the original press release on ACCESS Newswire

ISTANBUL, TR / ACCESS Newswire / June 11, 2025 / Hair transplants have become more visible, more available, and more consistent. Social media is filled with results. Clinics promote short recovery, natural density, and streamlined procedures. For people considering treatment, the message sounds clear: the process is simple.

It isn’t.

Behind the advertising is a procedure that still depends on real planning, surgical skill, and structure. The technology is better. Patient awareness is better. But too often, the conversation skips the part that matters: what happens before, during, and after the surgery.

Demand Is High, So Is the Risk of Assumptions

Hair loss affects millions of men and women across the U.S. As more people seek treatment, more clinics enter the market. That expansion brings volume, not always quality.

Some clinics reduce costs by handing off critical tasks to non-specialized staff. Others deliver inconsistent outcomes because their processes aren’t built around evaluation or recovery.

Results depend on the team, the training, and how each case is managed from consultation to recovery.

What to Ask Before Moving Forward

Strong clinics take time during the consultation and provide clear answers to every question. Here are four that matter:

• Who performs the procedure? Not the brand, the individual.

• How is the hairline designed? Every face and hair type requires its own plan.

• What is the process for managing grafts? Quantity means little without direction.

• How is recovery monitored? Healing takes time, and oversight protects results.

The best responses are direct, detailed, and backed by consistent planning.

Planning Beats Promotion

Hair transplants are often sold as fast and predictable. The results depend on biology. Hair grows in cycles. Full development takes months. Any clinic that pushes speed over evaluation risks long-term disappointment.

Experienced teams understand how to pace the process. They prioritize steady improvement, not instant change. That mindset lowers risk and improves satisfaction. A strong result holds up over time and stays in harmony with future changes.

How Vera Clinic Aligns Process with Results

Vera Clinic, based in Istanbul, follows a protocol built around transparency. Their work begins with detailed imaging and patient-specific evaluation. Each case receives a mapped plan, no estimates, no templates.

Grafts are analyzed with magnification before placement. This verifies integrity and helps ensure direction and density match the original growth pattern.

Surgical work is followed by guided recovery. Post-surgical care is built around specific steps tailored to the patient’s case. Follow-ups are scheduled. Progress is reviewed in measurable phases. Healing support is provided through OxyCure Therapy, which increases oxygen around the treated area and supports graft survival.

Vera’s system is designed for accountability. They work with patients from the U.S. and across Europe, and every case is handled with the same structure.

Their reputation is built on execution. The work holds up over time because the foundation is clear.

Patients Set the Tone by Asking the Right Questions

The strongest outcomes start long before surgery. They start in the consultation room or on the first call. Patients who ask direct questions are more likely to avoid rushed planning, unrealistic expectations, and overused strategies.

Hair restoration relies on planning, routine, and accurate follow-up.

Results Follow the Plan, Not the Pitch

Quick fixes lead to results that age poorly or feel out of place.

Patients who take time to understand the process and choose based on planning see the strongest long-term results. A good result reflects more than new growth. It reflects how the patient was treated throughout the experience.

Media Contact:
Company: Vera Clinic
Name: Mouheb Bouzgarrou
Email: info@www.veraclinic.net
Address: İstanbul Turkey

SOURCE: Vera Clinic

View the original press release on ACCESS Newswire

KITCHENER, ON / ACCESS Newswire / June 11, 2025 / Cloud DX Inc. (“Cloud DX”) (TSXV:CDX)(OTCQB:CDXFF) reports that it has received a Cease Trade Order from the Ontario Securities Commission (OSC) on May 7, 2025. The order was issued due to the inability of the Company to file audited financial statements for FY2024.

Trading of shares of the Company was initially halted when a subsidiary of the Company filed a Notice of Intention to Make a Proposal (the “NOI”) under the Bankruptcy and Insolvency Act (the “BIA”) on June 6, 2024. Following a court-supervised Sale and Investment Solicitation Process (the “SISP”) the Company reported the sale of its wholly-owned subsidiary Cloud Diagnostics Canada ULC (“Cloud Canada”) to 1493907 B.C. Ltd (the “Purchaser”) under a Reverse Vesting Order (the “RVO”) granted in BC Supreme Court on November 19, 2024. With the closing of the RVO Transaction on December 13, 2024, the Company ceased operations, and all assets of the Company were transferred to the Purchaser. On May 27, 2025 the Company’s board of directors was dissolved.

Further information regarding the Transaction and documents related thereto can be accessed through the website hosted by Crowe MacKay & Company Ltd. in its capacity as proposal trustee for Cloud Canada: https://crowemackayco.ca/project/cloud-diagnostics-canada-ulc/

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

# # #

Officer Responsible for this Press Release:

Robert Kaul
Chief Executive Officer
Phone 888-543-0944
robert.kaul@clouddx.com

Forward Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. In particular, this news release includes certain forward-looking statements concerning the terms of the contract extension, the expected proceeds therefrom, as well as management’s objectives, strategies, beliefs and intentions.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, the Company’s the ability of the Company to fulfill the terms of and derive the benefits from the contract extension.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information.

À propos de Cloud DX

Accélérant les soins de santé virtuels, Cloud DX a pour mission d’améliorer les soins de santé pour tous. Notre plateforme de surveillance à distance des patients Connected HealthMC est utilisée par des entreprises de soins de santé et des équipes de soins partout en Amérique du Nord pour gérer virtuellement les maladies chroniques, permettre aux gens de vieillir chez eux et fournir des soins post-chirurgicaux de qualité hospitalière à domicile. Nos partenaires obtiennent de meilleurs résultats pour les soins de santé et les patients, réduisent le besoin d’hospitalisation ou de réadmission, et réduisent les coûts de prestation des soins de santé grâce à une utilisation plus efficace des ressources. Cloud DX est co-lauréate du prix Qualcomm Tricorder XPRIZE, lauréate du prix Edison 2021, finaliste du concours « World Changing Idea » de Fast Company et un des dix plus importants fournisseurs de télésanté au Canada.

Site des relations avec les investisseurs de Cloud DX https://ir.clouddx.com/overview/default.aspx

La Bourse de croissance TSX et son fournisseur de services de réglementation (tel que ce terme est défini dans les politiques de la Bourse de croissance TSX) n’assument aucune responsabilité quant à la pertinence ou à l’exactitude du présent communiqué.

Tous les énoncés prospectifs sont assujettis à des risques et à des incertitudes, tels que ceux décrits dans les rapports périodiques de Medtronic déposés auprès de la Securities and Exchange Commission. Les résultats réels peuvent sensiblement différer des résultats anticipés.

SOURCE: Cloud DX Inc.

View the original press release on ACCESS Newswire

Filming Begins Thursday, June 12 at the New York Stock Exchange – Campaign Includes National TV Coverage, Earned Media, TV Commercials, and Full Social Media Amplification

NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / New to The Street, one of the nation’s longest-running business television platforms, proudly announces a new multi-part media series spotlighting Lahontan Gold Corp. (TSX-V:LG)(OTCQB:LGCXF) and its Founder, President, and CEO Kimberly Ann Arntson. The new campaign begins filming Thursday, June 12th from the iconic New York Stock Exchange (NYSE) and will feature national television broadcasts, earned media placements, custom-produced commercials, and expansive social media distribution across all major platforms.

The announcement marks a renewed and expanded collaboration between Lahontan Gold and New to The Street, building on prior successful media appearances. As part of this enhanced engagement, the series will integrate New to The Street’sNewsOut™ video press release platform, increasing the company’s visibility to institutional investors, retail audiences, and global media outlets.

“We know we’re doing something right when great clients like Lahontan keep coming back and expanding into our new media offerings like NewsOut and TV commercials,” said Vince Caruso, Creator and Executive Producer of New to The Street. “Kimberly Ann is a standout executive in the gold sector, and we’re honored to help bring her story and vision to our national audience.”

The new series will air as sponsored programming on Fox Business Network and Bloomberg Television, and will be distributed to New to The Street’s rapidly growing base of over 2.5 million YouTube subscribers. In addition, select segments will be amplified through outdoor placements across Times Square, Wall Street, and midtown Manhattan, as well as through targeted media placements with ABC, NBC, CBS, and FOX local affiliates.

The content will feature in-depth interviews with Kimberly Ann Arntson, highlighting Lahontan’s exploration strategy in Nevada’s prolific Walker Lane District, ongoing drilling results, and the company’s plans for growth and shareholder value creation.

Broadcast air dates and digital release schedules will be announced in the coming days.

About Lahontan Gold Corp.
Lahontan Gold Corp. is a Canadian exploration company focused on the development of high-grade gold and silver assets in Nevada. The company’s flagship Santa Fe Project lies within the highly prospective Walker Lane District, a region renowned for its rich mining history and ongoing gold discoveries. Led by CEO Kimberly Ann Arntson, Lahontan is rapidly advancing its exploration efforts to unlock shareholder value through responsible and aggressive project development.

Website: www.lahontangoldcorp.com

About New to The Street
New to The Street is a nationally recognized media platform that produces and distributes in-depth interviews and features on innovative public and private companies. Now in its 16th year, the show airs weekly as sponsored programming on Bloomberg Television, Fox Business Network, and digital outlets. With over 2.5 million YouTube subscribers, iconic Times Square billboard presence, and media partnerships across major networks, New to The Street is the go-to outlet for executive storytelling and financial news. The platform also manages NewsOut™, a leading video press release syndication service that combines visual content with guaranteed media reach.

For media inquiries or interview opportunities:
Monica Brennan
PR Director, New to The Street
Monica@NewToTheStreet.com

Follow New to The Street on Social Media:
YouTube:@NewtotheStreetTV
LinkedIn: New to The Street TV
Twitter/X: @NewToTheStreet
Instagram: @NewToTheStreetTV
Facebook: @NewToTheStreetMedia

SOURCE: New To The Street

View the original press release on ACCESS Newswire

LAS VEGAS, NV / ACCESS Newswire / June 11, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1), a fintech specializing in turnkey, crypto-related solutions for institutions and merchants, is pleased to announce its participation in iFX EXPO International, taking place June 11, 2025, in Limassol, Cyprus.

ALT5 Sigma will exhibit at Booth #97 and is proud to be back for a second year at this flagship event. iFX EXPO has become the premier gathering in the online trading industry, setting a high standard for excellence.

ALT5’s infrastructure powers real-time stablecoin settlement, crypto payment processing, and digital asset rails for use cases ranging from cross-border merchant payments to API-driven fintech integrations and FX and trading desks seeking digital asset exposure.

“We’re excited to participate in iFX EXPO International, a premier event that brings together the brightest minds in fintech and trading. At ALT5, we’re passionate about advancing digital asset integration, and this expo offers a fantastic opportunity to connect, collaborate, and showcase how our technology is helping shape the future of finance,” said Peter Tassiopoulos, CEO of ALT5 Sigma.

Built for Scale, Designed for Compliance

ALT5 delivers an API-first, custody-ready infrastructure that enables real-time settlement, stablecoin-based payments, and digital asset capabilities at scale. Used by fintechs, payment processors, FX, trading desks, and neobanks, ALT5’s platform supports enterprise-grade integration, while aligning with evolving regulatory frameworks.

Whether building new rails for programmable payments or navigating compliant access to digital assets, ALT5 helps bridge traditional finance with emerging digital systems-offering tools designed for institutional-grade deployment.

Meet ALT5 Sigma at iFX EXPO International 2025

The ALT5 team, and product specialists, will be on-site for live demos, partner meetings, and ecosystem conversations throughout the event.

To connect, please reach out to info@alt5sigma.com or stop by Booth # 97 on the show floor.

About ALT5 Sigma Corporation

ALT5 Sigma Corporation (NASDAQ:ALTS) (FRA:5AR1) is a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing settlement, payment, and safe keeping of digital assets. ALT5 has been a constituent of the Russell Microcap Index since June 28, 2024.

Founded in 2018, ALT5 Sigma, Inc. (a wholly owned subsidiary of ALT5 Sigma Corporation) enables the migration to a new global financial paradigm through its suite of blockchain infrastructure technologies. ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms: “ALT5 Pay” and “ALT5 Prime.” The Company has processed over $5 billion USD in cryptocurrency transactions since inception.

ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets.

ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named “ALT5 Pro” that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime’s FIX API, as well as through Broadridge Financial Solutions’ NYFIX gateway for approved customers.

The Company is also advancing the separation of its biotech business, which will continue under “Alyea Therapeutics Corporation.” Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. Our patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted Jan123 Orphan Drug Designation for treatment of CRPS.

Forward Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5’s platforms and business, that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5’s services, and technology challenges for future growth or expansion. This press release also may contain statements and links relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as “continue”, “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “potential”, and other similar expressions. Such statements reflect the Company’s current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.

Many factors could cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release. Such factors could include, among others, those detailed in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the sections entitled “Risk Factors” in the Company’s filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Media/Investor Relations Contact

IR@alt5sigma.com
1-800-400-2247

SOURCE: ALT5 Sigma Corp.

View the original press release on ACCESS Newswire

A Smarter Way to Answer Every Call. Powered by AI, Backed by Human Expertise.

LAS VEGAS, NV / ACCESS Newswire / June 11, 2025 / Abby Connect, a recognized leader in premium receptionist services, is proud to announce the launch of Abby AI Receptionist: a groundbreaking, 24/7 AI answering service powered by two decades of human receptionist experience. Abby AI Receptionist helps businesses reliably capture more leads, delight customers, and reduce operational costs without sacrificing the personal touch.

Unlike standard chatbots or purely tech-driven AI assistants, Abby AI Receptionist is uniquely trained from millions of actual human receptionist interactions. Fluent in English and Spanish, it provides businesses with a smarter, scalable solution to the estimated $75 billion in annual losses from missed calls and poor first impressions.

“Small businesses don’t need another generic AI bot-they need an intelligent receptionist solution trained from real-world conversations,” said Nathan Strum, CEO of Abby Connect. “Abby AI offers exactly that: authentic conversations, real-time responsiveness, and our exclusive Human Backup On-Demand to seamlessly escalate calls whenever needed. It’s the first AI built specifically by and for service professionals.”

More Than a Virtual Assistant: An AI Trained by Humans

Designed for busy professionals in law, real estate, franchise operations, trades, consulting, and other service-based businesses, Abby AI Receptionist delivers:

• 24/7 Call Answering: Capture leads and client calls around-the-clock in English and Spanish.

• Advanced Lead Capture: Intelligent new-client intake and qualification.

• Human Backup On-Demand: Abby Connect’s unique guarantee-complex or sensitive calls seamlessly transfer to live U.S.-based receptionists.

• Smart Routing & Integration: Calls intelligently directed based on urgency or department, integrated seamlessly into CRMs, calendars, and business apps.

• Customized FAQs & Scripts: Tailored specifically for each business, improving call outcomes.

“Our clients need reliable after-hours coverage and AI that actually sounds human, without babysitting technology,” said Lisa Snyder, VP of Sales and Marketing. “Abby AI delivers exceptional caller experiences, helping our clients sleep easier knowing they’ll never miss another important call.”

Flexible Pricing and Risk-Free Trial

Businesses of any size can get started immediately with Abby AI’s freemium plan (limited monthly minutes included), and paid plans offer more comprehensive solutions at competitive rates-no setup fees required. To celebrate the launch, Abby Connect is offering a risk-free 14-day trial of Abby AI’s Starter, Essential, and Growth packages.

Experience Abby AI Receptionist today at https://www.abby.com/products/ai-receptionist/.

About Abby Connect
Founded in 2005, Abby Connect is a premier provider of live receptionist services and innovative AI-driven communication solutions. Abby helps businesses grow by making every conversation count, whether handled by a real person, Abby’s proprietary AI, or a seamless blend of both.

Media Contact:
press@abby.com | (877) 303-5757

SOURCE: Abby Connect

View the original press release on ACCESS Newswire

Two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of crofelemer from CID to treatment of general, non-infectious diarrhea in dogs

Jaguar in discussions with potential partners to license and fund development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S. and/or globally

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs

SAN FRANCISCO, CA / ACCESS Newswire / June 11, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), under its Jaguar Animal Health tradename for the veterinary market, today announced that the first study site has been established for Jaguar’s field study of Canalevia-CA1, Jaguar’s U.S. Food and Drug Administration (FDA) conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs.

Jaguar has two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) in dogs and to expand the indication of crofelemer from CID in dogs to treatment of general, non-infectious diarrhea in dogs. The company is in discussions with potential partners to fund development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S. and/or globally.

“We’ve been pleased with the marketplace reception of crofelemer for treatment of CID in dogs, and believe there is clearly an unmet medical need for a product for the much larger market of treatment of general, non-infectious diarrhea in dogs,” said Lisa Conte, Jaguar’s Founder and CEO. “We estimate that U.S. veterinarians see approximately six million annual cases of acute and chronic diarrhea in dogs, and we look forward to identifying a partner to fund and execute development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in the U.S and/or globally. Forging a partnership for this purpose is a key focus of our business development efforts in 2025 and has been designated as a key potential catalyst for the company this year.”

“Jaguar’s canine-focused business development efforts align with our ongoing business development efforts on the ‘human’ side of the company for crofelemer – the catalysts for which are the pathways discussed with the FDA to bring crofelemer to metastatic breast cancer patients, a population we feel meets the requirements for orphan drug status; and the prompt establishment of an expanded access program for crofelemer for the ongoing important unmet medical need of cancer therapy-related diarrhea in breast cancer patients; and the initial proof-of-concept results from the ongoing investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer in Abu Dhabi in pediatric patients with intestinal failure due to the orphan diseases microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF). As recently announced, the initial proof-of-concept results of this IIT show crofelemer reduced the required total parenteral nutrition (TPN) and/or supplementary intravenous fluids, collectively referred to as parenteral support, in patients with intestinal failure due to MVID and short bowel syndrome by up to 27% and 12.5% respectively.”

The objective of the prospective, randomized, open-label field study in dogs undergoing chemotherapy treatment across the U.S. is to collect real-world data to demonstrate real-world evidence of the clinical effectiveness for Canalevia-CA1 for the treatment of CID in dogs to support potential full FDA approval of the drug for this indication. Dogs enrolled in this study will be randomly assigned to receive a prescription of Canalevia-CA1 as a treatment for CID or be randomly selected to the control group.

As announced, Jaguar established a new Investigational New Animal Drug (INAD) file with the FDA’s Center for Veterinary Medicine for crofelemer to treat general, non-infectious diarrhea in dogs.

Diarrhea is one of the most common reasons for veterinary office visits for dogs and is the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drug to treat canine general, non-infectious diarrhea. According to the American Veterinary Medical Association, there were an estimated 89.7 million dogs in the United States in 2024, with nearly half (45.5%) of U.S. households owning a dog in 2024. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of control in urban settings where owners don’t have easy access to outdoor facilities is a significant problem for families with dogs.

Canalevia-CA1, a canine-specific formulation of crofelemer, Jaguar’s novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is available from multiple leading veterinary distributors in the U.S., including Chewy.

About Conditional Approval and Full Approval

Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA’s conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the “substantial evidence” standard of effectiveness for full approval. The conditional approval is valid for one year. The drug company can ask the FDA to renew the conditional approval annually for up to four more years, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving “substantial evidence of effectiveness” for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug.

About Chemotherapy-induced Diarrhea (CID) in Dogs

According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, and almost 50% of dogs over age 10 will develop cancer.¹ According to the National Cancer Institute, which is part of the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs each year in the U.S.

Due to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,² and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients’ chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.

Canalevia-CA1 is a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs.

About Canalevia^®-CA1

Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a “small number” threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use.

About Crofelemer

Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.

Important Safety Information About Canalevia^®-CA1

For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that it will identify a partner to fund and execute development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S and/or globally, Jaguar’s expectation that the U.S. population of metastatic breast cancer patients meets the requirements for orphan drug status, Jaguar’s expectation that it will promptly establish an expanded access program for crofelemer for cancer therapy-related diarrhea in breast cancer patients, and Jaguar’s expectation that the field study of Canalevia-CA1 for the treatment of CID in dogs will support potential full FDA approval of the drug for this indication. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

¹ “Cancer in Pets.” American Veterinary Medical Association, 2021, https://www.avma.org/resources/pet-owners/petcare/cancer-pets

² Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire